Pembrolizumab biosimilar (Laboratorio Elea Phoenix Sa)

帕博利珠单抗生物类似药（Laboratorio Elea Phoenix Sa）

Report date: 2026/03/12 20:00:16

Base Information

Drug NamePembrolizumab biosimilar (Laboratorio Elea Phoenix Sa)
Drug Alias NameMB12MB-12
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBosnia and HerzegovinaArmeniaPanama +[22] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesLaboratorio Elea Phoenix Sa
China Registration ClassN/A

Develop Information

Active CompaniesMabxience Research SLLaboratorio Elea Phoenix Sa
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeL01FF02L01XC18
Related LinksN/A